Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

(2017) P. M. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors

(2010) Italo Beria et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus

(2010) Zdenek Andrysik et al.   NUCLEIC ACIDS RESEARCH

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding

(2009) Kyle A. Emmitte et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors

(2009) Yoshiyuki Sato et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress

(2009) Fatih M. Uckun et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis

(2009) Wolfgang Reindl et al.   CHEMBIOCHEM

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

(2009) T Ikezoe et al.   LEUKEMIA

health services and public health

(2008)   ANNALS OF ONCOLOGY

Discovery of thiophene inhibitors of polo-like kinase

(2008) Kyle A. Emmitte et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Longitudinal analysis of heart and liver iron in thalassemia major

(2008) L. J. Noetzli et al.   BLOOD

Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions

(2008) Wolfgang Reindl et al.   CHEMISTRY & BIOLOGY

Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development

(2008) Tohru Takaki et al.   CURRENT OPINION IN CELL BIOLOGY

Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1

(2008) Mark Petronczki et al.   DEVELOPMENTAL CELL

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

(2008) P. Schöffski et al.   EJC SUPPLEMENTS

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia

(2008) Christine Didier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition

(2008) Nobumoto Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY